What is William Blair’s Forecast for VTGN Q1 Earnings?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) – Research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Vistagen Therapeutics in a report released on Thursday, November 7th. William Blair analyst M. Minter forecasts that the company will earn ($0.36) per share for the quarter. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Vistagen Therapeutics’ current full-year earnings is ($1.85) per share. William Blair also issued estimates for Vistagen Therapeutics’ Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.34) EPS.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.06. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.30 million. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%. During the same quarter in the prior year, the firm posted ($0.94) EPS.

Vistagen Therapeutics Stock Down 3.0 %

NASDAQ VTGN opened at $2.93 on Monday. The firm’s fifty day moving average price is $3.07 and its two-hundred day moving average price is $3.52. Vistagen Therapeutics has a 1 year low of $2.55 and a 1 year high of $5.86.

Institutional Investors Weigh In On Vistagen Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. StemPoint Capital LP grew its holdings in Vistagen Therapeutics by 3.3% during the first quarter. StemPoint Capital LP now owns 1,848,582 shares of the company’s stock worth $9,292,000 after purchasing an additional 58,400 shares during the period. Valence8 US LP bought a new stake in Vistagen Therapeutics in the 3rd quarter valued at $103,000. Acadian Asset Management LLC acquired a new stake in Vistagen Therapeutics during the 1st quarter valued at $169,000. Blair William & Co. IL boosted its position in Vistagen Therapeutics by 29.2% during the second quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock worth $308,000 after purchasing an additional 20,000 shares during the period. Finally, American Century Companies Inc. increased its holdings in shares of Vistagen Therapeutics by 49.1% in the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after purchasing an additional 9,984 shares during the last quarter. 78.39% of the stock is owned by institutional investors.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.